Third, the sample sizes of our CAA groups were not sufficient to allow subgroup analyses with tauopathy positive (increased phosphorylated tau (p-tau)) and tauopathy negative participants to assess the possible influence of co-existing AD. This evidence concerns the gene MAPT and Alzheimer disease.